Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery

Abstract Significant weight loss can modify the progression of Nonalcoholic fatty liver disease (NAFLD) with the most convincing evidence coming from bariatric surgery cohorts. Effective ways to non-invasively characterise NAFLD in these patients has been lacking, with high Fibroscan failure rates r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andrew Yang, Melinda Nguyen, Irene Ju, Anthony Brancatisano, Brendan Ryan, David van der Poorten
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/afce3ba567f84beabeb9527989019ee2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:afce3ba567f84beabeb9527989019ee2
record_format	dspace
spelling	oai:doaj.org-article:afce3ba567f84beabeb9527989019ee22021-12-02T15:23:16ZUtility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery10.1038/s41598-021-93294-62045-2322https://doaj.org/article/afce3ba567f84beabeb9527989019ee22021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93294-6https://doaj.org/toc/2045-2322Abstract Significant weight loss can modify the progression of Nonalcoholic fatty liver disease (NAFLD) with the most convincing evidence coming from bariatric surgery cohorts. Effective ways to non-invasively characterise NAFLD in these patients has been lacking, with high Fibroscan failure rates reported. We prospectively evaluated the utility of Fibroscan using XL-probe over a two-year period. 190 consecutive patients undergoing bariatric surgery were followed as part of their routine care. All patients had Fibroscan performed on the day of surgery and at follow-up a mean of 13 months (± 6.3) later. The majority of patients were female (82%) with mean age of 42. Fibroscan was successful in 167 (88%) at baseline and 100% at follow up. Patients with a failed Fibroscan had higher body mass index (BMI) and alanine transaminase (ALT), but no difference in FIB-4/NAFLD score. Mean baseline Liver stiffness measurement was 5.1 kPa, with 87% of patients classified as no fibrosis and 4% as advanced fibrosis. Mean baseline controlled attenuation parameter was 291, with 78% having significant steatosis, 56% of which was moderate-severe. Significant fibrosis was associated with higher BMI and HbA1c. Significant steatosis was associated with higher BMI, ALT, triglycerides and insulin resistance. Mean follow up time was 12 months with weight loss of 25.7% and BMI reduction of 10.4 kg/m2. Seventy patients had repeat fibroscan with reductions in steatosis seen in 90% and fibrosis in 67%. Sixty-four percent had complete resolution of steatosis. Fibroscan can be performed reliably in bariatric cohorts and is useful at baseline and follow-up. Significant steatosis, but not fibrosis was seen in this cohort with substantial improvements post-surgery.Andrew YangMelinda NguyenIrene JuAnthony BrancatisanoBrendan RyanDavid van der PoortenNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Andrew Yang Melinda Nguyen Irene Ju Anthony Brancatisano Brendan Ryan David van der Poorten Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
description	Abstract Significant weight loss can modify the progression of Nonalcoholic fatty liver disease (NAFLD) with the most convincing evidence coming from bariatric surgery cohorts. Effective ways to non-invasively characterise NAFLD in these patients has been lacking, with high Fibroscan failure rates reported. We prospectively evaluated the utility of Fibroscan using XL-probe over a two-year period. 190 consecutive patients undergoing bariatric surgery were followed as part of their routine care. All patients had Fibroscan performed on the day of surgery and at follow-up a mean of 13 months (± 6.3) later. The majority of patients were female (82%) with mean age of 42. Fibroscan was successful in 167 (88%) at baseline and 100% at follow up. Patients with a failed Fibroscan had higher body mass index (BMI) and alanine transaminase (ALT), but no difference in FIB-4/NAFLD score. Mean baseline Liver stiffness measurement was 5.1 kPa, with 87% of patients classified as no fibrosis and 4% as advanced fibrosis. Mean baseline controlled attenuation parameter was 291, with 78% having significant steatosis, 56% of which was moderate-severe. Significant fibrosis was associated with higher BMI and HbA1c. Significant steatosis was associated with higher BMI, ALT, triglycerides and insulin resistance. Mean follow up time was 12 months with weight loss of 25.7% and BMI reduction of 10.4 kg/m2. Seventy patients had repeat fibroscan with reductions in steatosis seen in 90% and fibrosis in 67%. Sixty-four percent had complete resolution of steatosis. Fibroscan can be performed reliably in bariatric cohorts and is useful at baseline and follow-up. Significant steatosis, but not fibrosis was seen in this cohort with substantial improvements post-surgery.
format	article
author	Andrew Yang Melinda Nguyen Irene Ju Anthony Brancatisano Brendan Ryan David van der Poorten
author_facet	Andrew Yang Melinda Nguyen Irene Ju Anthony Brancatisano Brendan Ryan David van der Poorten
author_sort	Andrew Yang
title	Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
title_short	Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
title_full	Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
title_fullStr	Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
title_full_unstemmed	Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
title_sort	utility of fibroscan xl to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/afce3ba567f84beabeb9527989019ee2
work_keys_str_mv	AT andrewyang utilityoffibroscanxltoassesstheseverityofnonalcoholicfattyliverdiseaseinpatientsundergoingbariatricsurgery AT melindanguyen utilityoffibroscanxltoassesstheseverityofnonalcoholicfattyliverdiseaseinpatientsundergoingbariatricsurgery AT ireneju utilityoffibroscanxltoassesstheseverityofnonalcoholicfattyliverdiseaseinpatientsundergoingbariatricsurgery AT anthonybrancatisano utilityoffibroscanxltoassesstheseverityofnonalcoholicfattyliverdiseaseinpatientsundergoingbariatricsurgery AT brendanryan utilityoffibroscanxltoassesstheseverityofnonalcoholicfattyliverdiseaseinpatientsundergoingbariatricsurgery AT davidvanderpoorten utilityoffibroscanxltoassesstheseverityofnonalcoholicfattyliverdiseaseinpatientsundergoingbariatricsurgery
_version_	1718387285164032000

Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery

Ejemplares similares